ABVC Biopharma Inc
ABVC2.910USD
+0.160+5.82%
Market hours （ET）Quotes delayed by 15 min
44.75MMarket Cap
LossP/E TTM
More Details of ABVC Biopharma Inc Company
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.
Company Info
Ticker SymbolABVC
Company nameABVC Biopharma Inc
IPO dateNov 09, 2004
CEODr. Uttam Yashwant Patil
Number of employees16
Security typeOrdinary Share
Fiscal year-endNov 09
Address44370 Old Warm Springs Blvd
CityFREMONT
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94538-6148
Phone15106680881
Websitehttps://abvcpharma.com/
Ticker SymbolABVC
IPO dateNov 09, 2004
CEODr. Uttam Yashwant Patil
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Shuling Jiang
Ms. Shuling Jiang
Director
Director
1.00M
+3.82%
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Chief Scientific Officer, Chief Strategy Officer, Director
Chief Scientific Officer, Chief Strategy Officer, Director
375.99K
-11.15%
Mr. Eugene Jiang
Mr. Eugene Jiang
Chairman of the Board, Chief Business Officer
Chairman of the Board, Chief Business Officer
131.16K
--
Mr. Yoshinobu Odaira
Mr. Yoshinobu Odaira
Independent Director
Independent Director
57.76K
--
Dr. Chang-Jen Jiang, M.D.
Dr. Chang-Jen Jiang, M.D.
Director
Director
42.03K
-0.12%
Dr. Tsang Ming Jiang, Ph.D.
Dr. Tsang Ming Jiang, Ph.D.
Director
Director
41.99K
--
Ms. Yen-Hsin Chou
Ms. Yen-Hsin Chou
Independent Director
Independent Director
41.96K
--
Ms. Norimi Sakamoto
Ms. Norimi Sakamoto
Independent Director
Independent Director
41.85K
--
Ms. Hsin-Hui Miao
Ms. Hsin-Hui Miao
Independent Director
Independent Director
41.51K
-13.66%
Mr. Yu- Min (Francis) Chung
Mr. Yu- Min (Francis) Chung
Independent Director
Independent Director
41.39K
-1.33%
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Shuling Jiang
Ms. Shuling Jiang
Director
Director
1.00M
+3.82%
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Chief Scientific Officer, Chief Strategy Officer, Director
Chief Scientific Officer, Chief Strategy Officer, Director
375.99K
-11.15%
Mr. Eugene Jiang
Mr. Eugene Jiang
Chairman of the Board, Chief Business Officer
Chairman of the Board, Chief Business Officer
131.16K
--
Mr. Yoshinobu Odaira
Mr. Yoshinobu Odaira
Independent Director
Independent Director
57.76K
--
Dr. Chang-Jen Jiang, M.D.
Dr. Chang-Jen Jiang, M.D.
Director
Director
42.03K
-0.12%
Dr. Tsang Ming Jiang, Ph.D.
Dr. Tsang Ming Jiang, Ph.D.
Director
Director
41.99K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Jiang (Shuling)
5.98%
YuanGene, Corp
4.95%
Jiang (Tsung-Shann)
2.24%
Jiang (Eugene)
0.78%
Geode Capital Management, L.L.C.
0.62%
Other
85.43%
Shareholders
Shareholders
Proportion
Jiang (Shuling)
5.98%
YuanGene, Corp
4.95%
Jiang (Tsung-Shann)
2.24%
Jiang (Eugene)
0.78%
Geode Capital Management, L.L.C.
0.62%
Other
85.43%
Shareholder Types
Shareholders
Proportion
Individual Investor
11.52%
Corporation
4.95%
Investment Advisor
1.02%
Investment Advisor/Hedge Fund
0.81%
Venture Capital
0.36%
Hedge Fund
0.08%
Other
81.25%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
34
3.14M
18.75%
-459.62K
2025Q1
36
3.18M
25.48%
-443.49K
2024Q4
37
3.35M
25.84%
-140.63K
2024Q3
38
3.28M
25.33%
-177.84K
2024Q2
39
3.21M
27.30%
-361.06K
2024Q1
37
3.25M
30.84%
+1.04M
2023Q4
37
1.92M
24.18%
+3.24K
2023Q3
39
1.80M
52.80%
+194.05K
2023Q2
37
1.48M
44.76%
-133.59K
2023Q1
36
1.48M
44.98%
+2.69K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Jiang (Shuling)
1.00M
5.98%
+36.89K
+3.82%
Apr 28, 2025
YuanGene, Corp
829.70K
4.95%
--
--
May 27, 2025
Jiang (Tsung-Shann)
375.99K
2.24%
-47.17K
-11.15%
Apr 28, 2025
Jiang (Eugene)
131.16K
0.78%
--
--
May 27, 2025
Geode Capital Management, L.L.C.
104.48K
0.62%
+25.20K
+31.78%
Mar 31, 2025
The Lind Partners, LLC
94.99K
0.57%
-105.06K
-52.52%
Dec 31, 2024
Patil (Uttam)
72.43K
0.43%
--
--
Apr 28, 2025
XTX Markets LLC
60.44K
0.36%
+26.03K
+75.67%
Mar 31, 2025
Odaira (Yoshinobu)
57.76K
0.34%
--
--
Apr 28, 2025
The Vanguard Group, Inc.
46.95K
0.28%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Date
Type
Ratio
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
